Reviva Pharmaceuticals' (RVPH) "Buy" Rating Reiterated at HC Wainwright

Key Points

• HC Wainwright reiterated a "Buy" rating on Reviva with a $4.00 price target, while the consensus from analysts is a "Moderate Buy" with an average target of $3.86 (1 Strong Buy, 7 Buy, 1 Sell).
• The FDA has requested a second Phase 3 trial for brilaroxazine, triggering a regulatory delay that sent the stock down roughly 45.5% and prompted Roth to say Reviva may need an additional $60M–$75M of funding and to cut its price target to $1.50.
• Reviva is a small‑cap name trading around $0.32 with a market cap of about $37M and institutional ownership of ~63%, highlighting significant financing and dilution risk if large study funding is required.

Reviva Pharmaceuticals (NASDAQ:RVPH - Get Free Report)'s stock had its "buy" rating reiterated by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $4.00 price objective on the stock.

Several other analysts have also weighed in on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Reviva Pharmaceuticals in a report on Wednesday, October 8th. Benchmark cut their price objective on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a "speculative buy" rating on the stock in a report on Monday, September 15th. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a "sell" rating in a research report on Saturday, October 4th. Chardan Capital raised Reviva Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, November 19th. Finally, D. Boral Capital reissued a "buy" rating and set a $2.00 target price on shares of Reviva Pharmaceuticals in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $3.86.

Reviva Pharmaceuticals Stock Down 45.5%

Reviva Pharmaceuticals stock opened at $0.32 on Tuesday. Reviva Pharmaceuticals has a 12 month low of $0.25 and a 12 month high of $2.17. The stock has a market cap of $36.97 million, a P/E ratio of -0.70 and a beta of -0.02. The company's fifty day simple moving average is $0.57 and its 200-day simple moving average is $0.52.

Reviva Pharmaceuticals (NASDAQ:RVPH - Get Free Report) last issued its earnings results on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.05. On average, equities research analysts expect that Reviva Pharmaceuticals will post -0.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RVPH. NewEdge Advisors LLC acquired a new position in Reviva Pharmaceuticals during the first quarter worth $58,000. Geode Capital Management LLC lifted its stake in Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company's stock valued at $171,000 after purchasing an additional 29,063 shares during the last quarter. Persistent Asset Partners Ltd grew its holdings in Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company's stock worth $244,000 after purchasing an additional 480,864 shares during the period. XTX Topco Ltd bought a new stake in Reviva Pharmaceuticals in the second quarter valued at approximately $31,000. Finally, Armistice Capital LLC bought a new stake in Reviva Pharmaceuticals in the second quarter valued at approximately $1,026,000. Institutional investors and hedge funds own 63.18% of the company's stock.

Reviva Pharmaceuticals News Summary

Here are the key news stories impacting Reviva Pharmaceuticals this week:

• Positive Sentiment: Large, unusual call‑option activity — Investors bought roughly 25,745 call options (≈+295% vs. average), suggesting speculative bullish bets or hedging that could provide short‑term buying support. Traders Purchase High Volume of Call Options on Reviva Pharmaceuticals
• Positive Sentiment: Analyst support remains — D. Boral Capital reaffirmed a “buy” rating and a $2.00 price target, signaling at least one analyst believes recovery upside exists from current levels. D Boral Capital maintains Reviva Pharmaceuticals Holdings (RVPH) buy recommendation
• Negative Sentiment: FDA requested a second Phase 3 trial for brilaroxazine — The company disclosed written FDA feedback recommending an additional Phase 3 to generate more efficacy/safety data before an NDA submission, a major regulatory delay and cost driver. Reviva Announces Regulatory Update
• Negative Sentiment: Material funding need implied — Roth Capital estimates Reviva may require an additional $60M–$75M to complete the schizophrenia study, raising dilution and financing risk for shareholders. Roth says Reviva may need additional $60M-$75M for schizophrenia study
• Negative Sentiment: Price target cut and market reaction — Roth lowered its price target to $1.50 from $3, and coverage highlighted an immediate sell‑off after the FDA news; those moves reflect diminished near‑term valuation and higher perceived execution risk. Reviva Pharmaceuticals price target lowered to $1.50 from $3 at Roth Capital
• Negative Sentiment: Market headlines and coverage explain the sharp drop — Multiple outlets reported the stock plunge and explained the catalyst as the FDA request and funding concerns, which can amplify selling pressure. Reviva stock plunges after FDA requests second Phase 3 Why did RVPH stock crash 50% today?

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc NASDAQ: RVPH is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company's core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.